Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Patients not previously exposed to imatinib and with resistant or refractory Ph+ ALL,
lymphoid blast crisis chronic myelogenous leukaemia (LBC CML) or with de novo Ph+ ALL and
aged over 55y were eligible in the study. The DIV regimen consisted in one IV injection of
vincristine 2 mg combined with 2 days of dexamethasone 40 mg PO repeated weekly for 4 weeks
as induction and then monthly for 4 months as consolidation. Imatinib was administered at 800
mg per day during the induction period and at 600 mg/d continuously during consolidation.
Patients in CR not eligible for HSCT were allocated to maintenance therapy consisting in
weekly SC injection of Pegasys 45 µg and continuous administration of imatinib 400 mg per day
for 2 years.